Entera Bio Ltd. (NASDAQ:ENTX) Short Interest Update

Entera Bio Ltd. (NASDAQ:ENTX) was the target of a large increase in short interest during the month of October. As of October 31st, there was short interest totalling 44,200 shares, an increase of 9.4% from the October 15th total of 40,400 shares. Based on an average trading volume of 31,500 shares, the short-interest ratio is currently 1.4 days.

Institutional Trading of Entera Bio

Hedge funds have recently modified their holdings of the stock. Virtu Financial LLC acquired a new position in Entera Bio during the 1st quarter worth $37,000. Signature Estate & Investment Advisors LLC acquired a new position in shares of Entera Bio during the third quarter valued at $90,000. Finally, Parkman Healthcare Partners LLC lifted its stake in shares of Entera Bio by 2.4% during the third quarter. Parkman Healthcare Partners LLC now owns 411,076 shares of the company’s stock valued at $781,000 after acquiring an additional 9,558 shares during the period. 14.11% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective on shares of Entera Bio in a research report on Monday, November 11th.

Entera Bio Stock Down 2.8 %

NASDAQ:ENTX traded down $0.05 during mid-day trading on Friday, reaching $1.73. 17,923 shares of the company were exchanged, compared to its average volume of 128,627. Entera Bio has a 12 month low of $0.52 and a 12 month high of $3.35. The company has a fifty day moving average of $1.85 and a 200 day moving average of $1.91.

Entera Bio Company Profile

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures.